The importance of galectin-3 as a novel target for lung cancer patients harboring KRAS mutation

Precision cancer medicine using molecular targeted therapies is a cornerstone for cancer therapy during the last two decades. However, the drug resistance regardless of primary or acquired one is still a big hurdle which should be overcome to improve cancer therapy and its outcomes. In this regard, lung cancer is a prototype.